Mikkel Wandahl Pedersen
Hoofd Techniek/Wetenschap/O&O bij NYKODE THERAPEUTICS
Profiel
Mikkel Wandahl Pedersen is currently the Chief Scientific Officer at Nykode Therapeutics ASA since 2021.
Previously, he worked as the Chief Scientific Officer at Symphogen A.
He holds a doctorate degree from the University of Copenhagen.
Actieve functies van Mikkel Wandahl Pedersen
| Bedrijven | Functie | Begin |
|---|---|---|
| NYKODE THERAPEUTICS | Hoofd Techniek/Wetenschap/O&O | 01-06-2021 |
Eerdere bekende functies van Mikkel Wandahl Pedersen
| Bedrijven | Functie | Einde |
|---|---|---|
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Mikkel Wandahl Pedersen
| University of Copenhagen | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| NYKODE THERAPEUTICS | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |